Since,O
January,DATE
2020,DATE
Elsevier,PERSON
has,O
created,O
a,O
COVID,O
‐,O
19,NUMBER
resource,O
cen,O
‐,O
tre,O
with,O
free,O
information,O
in,O
English,NATIONALITY
and,O
Mandarin,O
on,O
the,O
novel,O
coronavirus,O
COVID19,O
.,O
The,O
COVID,O
‐,O
19,NUMBER
resource,O
centre,O
is,O
hosted,O
on,O
Elsevier,O
Connect,O
.,O
the,O
company,O
’s,O
public,O
news,O
and,O
information,O
web,O
‐,O
site,O
.,O
Elsevier,PERSON
hereby,O
grants,O
permission,O
to,O
make,O
all,O
its,O
COVID,O
‐,O
19,NUMBER
‐,O
related,O
research,O
that,O
is,O
available,O
on,O
the,O
COVID,O
‐,O
19,NUMBER
re,O
‐,O
source,O
centre,O
‐,O
including,O
this,O
research,O
content,O
‐,O
immediately,O
available,O
in,O
PubMed,O
Central,O
and,O
other,O
publicly,O
funded,O
reposito,O
‐,O
ries,O
.,O
such,O
as,O
the,O
WHO,O
COVID,O
database,O
with,O
rights,O
for,O
unrestricted,O
research,O
re,O
‐,O
use,O
and,O
analyses,O
in,O
any,O
form,O
or,O
by,O
any,O
means,O
with,O
ac,O
‐,O
knowledgement,O
of,O
the,O
original,O
source,O
.,O
These,O
permissions,O
are,O
granted,O
for,O
free,O
by,O
Elsevier,O
for,O
as,O
long,O
as,O
the,O
COVID,O
‐,O
19,NUMBER
resource,O
centre,O
remains,O
active,O
.,O
Effects,O
of,O
Hydroxychloroquine,O
Treatment,O
on,O
QT,O
Interval,O
Matthew,PERSON
Hooks,PERSON
.,O
MD,STATE_OR_PROVINCE
.,O
Bradley,PERSON
Bart,PERSON
.,O
MD,STATE_OR_PROVINCE
.,O
Orly,CITY
Vardeny,LOCATION
.,O
PharmD,O
.,O
MS,STATE_OR_PROVINCE
.,O
Anders,PERSON
Westanmo,PERSON
.,O
PharmD,O
.,O
MBA,O
.,O
Seluk,PERSON
Adabag,PERSON
.,O
MD,STATE_OR_PROVINCE
.,O
MS,STATE_OR_PROVINCE
To,O
appear,O
in,O
:,O
Heart,O
Rhythm,O
Revised,O
Date,O
:,O
during,O
the,O
production,O
process,O
.,O
errors,O
may,O
be,O
discovered,O
which,O
could,O
affect,O
the,O
content,O
.,O
and,O
all,O
legal,O
Effects,O
of,O
Hydroxychloroquine,O
Treatment,O
on,O
QT,O
In,O
‐,O
terval,O
Matthew,PERSON
Hooks,PERSON
.,O
MDa,O
.,O
Bradley,PERSON
Bart,PERSON
.,O
MDa,O
.,O
b,O
.,O
Orly,PERSON
Vardeny,PERSON
.,O
PharmD,O
.,O
MSa,O
.,O
c,O
.,O
Anders,PERSON
Westanmo,PERSON
.,O
PharmD,O
.,O
MBAd,O
.,O
Seluk,PERSON
Adabag,PERSON
.,O
MD,STATE_OR_PROVINCE
.,O
MSa,O
.,O
b,O
Cardiology,O
.,O
Minneapolis,ORGANIZATION
VA,ORGANIZATION
Health,ORGANIZATION
Care,ORGANIZATION
System,ORGANIZATION
.,O
Minneapolis,CITY
.,O
MN,STATE_OR_PROVINCE
.,O
USA,COUNTRY
;,O
cCenter,O
for,O
Care,ORGANIZATION
Delivery,ORGANIZATION
&,ORGANIZATION
Outcomes,ORGANIZATION
Research,ORGANIZATION
.,O
Minneapo,O
‐,O
lis,O
VA,ORGANIZATION
Health,ORGANIZATION
Care,ORGANIZATION
System,ORGANIZATION
.,O
Minneapolis,CITY
.,O
MN,STATE_OR_PROVINCE
.,O
USA,COUNTRY
;,O
Department,O
of,O
Pharmacy,O
.,O
Minneapolis,ORGANIZATION
VA,ORGANIZATION
Health,ORGANIZATION
Care,ORGANIZATION
System,ORGANIZATION
.,O
Minneapolis,CITY
.,O
MN,STATE_OR_PROVINCE
.,O
USA,COUNTRY
Brief,O
Title,O
:,O
Hydroxychloroquine,O
QT,O
Word,O
Count,TITLE
:,O
4139,DATE
Selcuk,O
Ad,O
‐,O
abag,O
.,O
MD,STATE_OR_PROVINCE
.,O
MS,STATE_OR_PROVINCE
One,NUMBER
Veterans,O
Drive,O
.,O
Division,O
of,O
Cardiology,O
(,O
111C,O
),O
Minneapolis,CITY
.,O
MN,STATE_OR_PROVINCE
55417,NUMBER
Dr.,O
Adabag,PERSON
has,O
obtained,O
research,O
grants,O
from,O
the,O
American,ORGANIZATION
Heart,ORGANIZATION
Association,ORGANIZATION
.,O
Medtronic,ORGANIZATION
Inc.,ORGANIZATION
.,O
Acknowledge,O
‐,O
ments,O
:,O
This,O
research,O
did,O
not,O
receive,O
specific,O
grant,O
from,O
funding,O
agencies,O
in,O
the,O
resources,O
and,O
use,O
of,O
facilities,O
of,O
the,O
Minneapo,O
‐,O
lis,O
VA,ORGANIZATION
Health,ORGANIZATION
Care,ORGANIZATION
System,ORGANIZATION
.,O
The,O
contents,O
do,O
not,O
represent,O
the,O
views,O
of,O
the,O
U.S.,ORGANIZATION
Department,ORGANIZATION
of,ORGANIZATION
Veterans,ORGANIZATION
Affairs,ORGANIZATION
or,O
the,O
United,ORGANIZATION
States,O
Background,O
Hydroxychloroquine,O
(,O
HCQ,O
),O
has,O
been,O
promoted,O
as,O
a,O
potential,O
treatment,O
for,O
COVID,O
‐,DATE
19,DATE
but,O
there,O
are,O
safety,O
concerns,O
.,O
Objectives,O
To,O
determine,O
the,O
effect,O
of,O
HCQ,O
treatment,O
on,O
QT,O
inter,O
‐,O
val,O
Methods,O
We,O
retrospectively,O
studied,O
the,O
electrocardiograms,O
of,O
819,NUMBER
patients,O
treated,O
with,O
HCQ,O
for,O
rheumatologic,O
diseases,CAUSE_OF_DEATH
from,O
2000,DATE
to,O
2020,DATE
.,O
The,O
primary,O
outcome,O
was,O
corrected,O
QT,O
(,O
QTc,O
),O
inter,O
‐,O
val,O
.,O
by,O
Bazett,PERSON
formula,O
.,O
during,O
HCQ,O
therapy,O
.,O
Results,O
The,O
patients,O
were,O
64.0,NUMBER
(,O
10.9,NUMBER
),O
years,DURATION
in,O
age,O
and,O
734,NUMBER
(,O
90,PERCENT
%,PERCENT
),O
were,O
men,O
.,O
The,O
median,O
dosage,O
and,O
duration,O
of,O
HCQ,O
were,O
400,NUMBER
mg,O
daily,SET
and,O
1006,DATE
(,O
471,NUMBER
‐,O
2075,DATE
),O
days,DURATION
.,O
respectively,O
.,O
The,O
mean,O
on,O
‐,O
treatment,O
QTc,O
was,O
430.9,NUMBER
(,O
31.8,NUMBER
),O
msec,O
.,O
In,O
total,O
.,O
55,NUMBER
(,O
7,PERCENT
%,PERCENT
),O
patients,O
had,O
QTc,O
470,NUMBER
‐,O
500,NUMBER
msec,O
and,O
12,NUMBER
(,O
1.5,PERCENT
%,PERCENT
),O
had,O
QTc,O
>,O
500msec,NUMBER
.,O
Chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
(,O
CKD,O
),O
.,O
history,O
of,O
atrial,O
fibrillation,O
(,O
AF,O
),O
and,O
heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
were,O
independent,RELIGION
risk,O
factors,O
for,O
prolonged,O
QTc,O
.,O
In,O
a,O
subset,O
of,O
591,NUMBER
patients,O
who,O
also,O
had,O
a,O
pre,O
‐,O
treatment,O
ECG,O
.,O
the,O
mean,O
QTc,O
increased,O
from,O
424.4,NUMBER
(,O
29.7,NUMBER
),O
msec,O
.,O
to,O
432.0,NUMBER
(,O
32.3,NUMBER
),O
msec,O
(,O
p,O
<,O
0.0001,NUMBER
),O
during,O
HCQ,O
treatment,O
.,O
Of,O
these,O
.,O
23,NUMBER
(,O
3.9,PERCENT
%,PERCENT
),O
patients,O
had,O
either,O
prolongation,O
of,O
QTc,O
>,O
15,PERCENT
%,PERCENT
or,O
an,O
on,O
‐,O
treatment,O
QTc,O
>,O
500,NUMBER
msec,O
.,O
Over,O
5.97,NUMBER
(,O
3.3310.11,NUMBER
),O
years,DURATION
of,O
follow,O
‐,O
up,O
.,O
269,NUMBER
(,O
33,PERCENT
%,PERCENT
),O
patients,O
died,O
.,O
QTc,O
>,O
470,NUMBER
msec,O
during,O
HCQ,O
treatment,O
was,O
associated,O
with,O
a,O
greater,O
mortality,O
risk,O
of,O
(,O
hazard,O
ratio,O
1.78,NUMBER
.,O
95,PERCENT
%,PERCENT
confidence,O
interval,O
1.16,NUMBER
‐,O
2.71,NUMBER
;,O
p,O
=,O
0.008,NUMBER
),O
in,O
uni,O
‐,O
variable,O
but,O
not,O
in,O
multivariable,O
analysis,O
.,O
Conclusion,O
Hydroxy,O
‐,O
chloroquine,O
is,O
associated,O
with,O
QT,O
prolongation,O
in,O
a,O
significant,O
fraction,O
of,O
patients,O
.,O
The,O
risk,O
of,O
QT,O
prolongation,O
is,O
higher,O
among,O
patients,O
with,O
CKD,O
.,O
AF,O
and,O
heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
who,O
may,O
benefit,O
from,O
greater,O
scrutiny,O
.,O
Keywords,O
:,O
long,O
QT,O
syndrome,O
;,O
drugs,CRIMINAL_CHARGE
;,O
drug,O
‐,O
in,O
‐,O
duced,O
arrhythmia,O
;,O
mortality,O
;,O
electrocardiogram,O
Since,O
December,DATE
2019,DATE
.,O
the,O
novel,O
single,O
‐,O
stranded,O
RNA,O
virus,O
known,O
as,O
the,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
‐,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
has,O
caused,O
millions,O
of,O
cases,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
a,O
global,O
pandemic,O
.,O
leading,O
to,O
substantial,O
morbidity,O
and,O
mortality1,O
.,O
Clini,O
‐,O
cal,O
trajectories,O
of,O
COVID,O
‐,O
19,NUMBER
vary,O
widely,O
.,O
with,O
worse,O
outcomes,O
ob,O
‐,O
served,O
in,O
older,O
individuals,O
and,O
those,O
with,O
concomitant,O
medical,O
conditions2,O
.,O
A,O
significant,O
proportion,O
of,O
hospitalized,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
have,O
cardiovascular,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
Moreover,O
.,O
COVID,O
‐,O
19,NUMBER
has,O
been,O
purported,O
to,O
cause,O
several,O
types,O
of,O
cardiac,O
adverse,O
events,O
.,O
including,O
myocardial,O
injury,O
.,O
acute,O
myocardial,CAUSE_OF_DEATH
infarction,CAUSE_OF_DEATH
.,O
acute,O
heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
myocarditis,CAUSE_OF_DEATH
.,O
and,O
arrhythmias35.There,O
is,O
no,O
ap,O
‐,O
proved,O
treatment,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
although,O
several,O
strategies,O
are,O
under,O
investigation,O
.,O
such,O
as,O
antivirals,O
.,O
antiretrovirals,O
.,O
immune,O
modulators,O
and,O
hydroxychloroquine,O
(,O
HCQ,O
),O
.,O
Originally,O
used,O
to,O
treat,O
malaria,CAUSE_OF_DEATH
.,O
HCQ,O
was,O
approved,O
for,O
the,O
treatment,O
of,O
systemic,O
lu,O
‐,O
pus,O
erythematosus,O
(,O
SLE,O
),O
by,O
the,O
FDA,ORGANIZATION
in,O
19556,NUMBER
.,O
It,O
is,O
currently,DATE
the,O
most,O
commonly,O
prescribed,O
medication,O
for,O
SLE,O
and,O
is,O
frequently,O
used,O
for,O
a,O
variety,O
of,O
other,O
rheumatologic,O
conditions,O
.,O
Cardiac,O
toxicity,O
is,O
rare,O
but,O
there,O
are,O
reports,O
of,O
conduction,O
abnormali,O
‐,O
ties,O
including,O
bundle,O
‐,O
branch,O
block,O
.,O
atrioventricular,O
block,O
.,O
QT,O
prolongation,O
.,O
torsade,O
de,O
pointes,O
.,O
and,O
sudden,O
cardiac,O
death710,O
.,O
There,O
is,O
in,O
vitro,O
evidence,O
that,O
chloroquine,O
and,O
HCQ,O
possess,O
an,O
‐,O
tiviral,O
properties11,O
.,O
These,O
data,O
have,O
been,O
extrapolated,O
to,O
hy,O
‐,O
pothesize,O
that,O
HCQ,O
may,O
prevent,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
and,O
attenuate,O
the,O
course,O
and,O
severity,O
of,O
the,O
COVID,O
‐,O
19,NUMBER
disease12,O
.,O
Indeed,O
.,O
on,O
March,DATE
28,DATE
.,DATE
2020,DATE
the,O
phosphate,O
),O
in,O
certain,O
hospitalized,O
patients,O
being,O
treated,O
for,O
COVID,O
‐,O
1913,DATE
.,O
However,O
.,O
recent,O
studies,O
showing,O
no,O
benefit,O
of,O
HCQ,O
in,O
COVID,O
‐,O
19,NUMBER
have,O
since,O
led,O
the,O
FDA,ORGANIZATION
to,O
remove,O
that,O
treated,O
with,O
HCQ,O
describe,O
significant,O
QT,O
prolongation,O
and,O
torsade,O
de,O
pointes,O
which,O
has,O
expanded,O
clinical,O
concern,O
regarding,O
the,O
ar,O
‐,O
rhythmogenic,O
risk,O
of,O
HCQ1821,O
.,O
The,O
purpose,O
of,O
this,O
study,O
is,O
to,O
provide,O
information,O
about,O
the,O
effects,O
of,O
HCQ,O
on,O
cardiac,O
conduc,O
‐,O
tion,O
abnormalities,O
that,O
appear,O
on,O
a,O
12,NUMBER
‐,O
lead,O
electrocardiogram,O
(,O
ECG,O
),O
.,O
Informed,O
consent,O
requirement,O
was,O
waived,O
.,O
Patient,O
Selec,O
‐,O
tion,O
We,O
identified,O
2665,DATE
patients,O
who,O
received,O
at,O
least,O
one,NUMBER
pre,O
‐,O
scription,O
for,O
HCQ,O
dispensed,O
at,O
the,O
Minneapolis,CITY
Veterans,O
Affairs,O
(,O
VA,ORGANIZATION
),ORGANIZATION
Health,ORGANIZATION
Care,ORGANIZATION
System,ORGANIZATION
from,O
the,DATE
year,DATE
2000,DATE
to,O
2020,DATE
.,O
Each,O
pre,O
‐,O
scription,O
represented,O
the,O
first,ORDINAL
dispense,O
of,O
HCQ,O
until,O
a,O
break,O
in,O
prescriptions,O
for,O
at,O
least,O
150,NUMBER
days22,O
.23,O
.,O
We,O
excluded,O
patients,O
without,O
an,O
ECG,O
performed,O
while,O
they,O
were,O
receiving,O
HCQ,O
treatment,O
(,O
n,O
=,O
1722,DATE
),O
.,O
After,O
also,O
excluding,O
the,O
124,NUMBER
duplicate,O
entries,O
.,O
we,O
in,O
‐,O
cluded,O
819,NUMBER
unique,O
patients,O
who,O
received,O
treatment,O
in,O
this,O
analy,O
‐,O
sis,O
.,O
All,O
ECGs,O
were,O
performed,O
with,O
the,O
General,ORGANIZATION
Electric,ORGANIZATION
MAC,ORGANIZATION
5000,NUMBER
and,O
stored,O
in,O
the,O
Marquette,O
Universal,O
System,O
for,O
Electrocardiog,O
‐,O
raphy,O
database24,O
.25,O
.,O
We,O
selected,O
the,O
first,ORDINAL
ECG,O
.,O
performed,O
at,O
least,O
5,DURATION
days,DURATION
after,O
starting,O
the,O
HCQ,O
treatment,O
for,O
analysis,O
.,O
When,O
present,DATE
.,O
we,O
also,O
analyzed,O
the,O
last,O
ECG,O
performed,O
before,O
starting,O
the,O
HCQ,O
treatment,O
.,O
We,O
recorded,O
the,O
ventricular,O
rate,O
.,O
QRS,O
dura,O
‐,O
tion,O
.,O
QT,O
interval,O
and,O
the,O
corrected,O
QT,O
interval,O
(,O
QTc,O
),O
calculated,O
via,O
the,O
Bazett,LOCATION
.,O
Framingham,CITY
and,O
Friderica,PERSON
formulas,O
.,O
For,O
patients,O
with,O
a,O
QRS,O
>,O
120,NUMBER
msec,O
we,O
used,O
the,O
Bogossian,MISC
formula26,O
to,O
calculate,O
a,O
modified,O
QT,O
interval,O
(,O
QTm,O
),O
.,O
QTm,O
=,O
QT,O
(,O
measured,O
),O
48.5,PERCENT
%,PERCENT
*,O
QRS,O
(,O
mea,O
‐,O
sured,O
),O
.,O
The,O
QTm,MISC
was,O
used,O
to,O
calculate,O
the,O
QTc,O
.,O
We,O
manually,O
mea,O
‐,O
sured,O
the,O
QT,O
interval,O
.,O
starting,O
from,O
the,O
beginning,O
of,O
the,O
Q,O
wave,O
to,O
the,O
end,O
of,O
the,O
T,O
wave,O
on,O
ECG,O
.,O
using,O
electronic,O
calipers,O
in,O
70,NUMBER
(,O
8.5,PERCENT
%,PERCENT
),O
randomly,O
selected,O
patients,O
in,O
the,O
cohort27,O
.,O
The,O
correla,O
‐,O
tion,O
coefficient,O
was,O
0.8,NUMBER
.,O
The,O
primary,O
outcome,O
variable,O
was,O
the,O
QTc,O
interval,O
during,O
HCQ,O
therapy,O
.,O
We,O
used,O
the,O
Bazett,O
formula,O
for,O
QT,O
correction,O
because,O
it,O
is,O
the,O
most,O
commonly,O
used,O
method,O
to,O
cal,O
‐,O
culate,O
QTc,O
.,O
QTc,O
>,O
470,NUMBER
msec,O
represents,O
the,O
99th,ORDINAL
percentile,O
of,O
QTc,O
distribution,O
in,O
the,O
general,TITLE
population,O
and,O
is,O
a,O
predictor,O
of,O
symptoms,O
in,O
patients,O
with,O
long,O
‐,O
QT,O
syndrome28,O
.29,O
.,O
QTc,O
>,O
500,NUMBER
msec,O
is,O
associated,O
with,O
a,O
higher,O
risk,O
of,O
life,O
‐,O
threatening,O
arrhyth,O
‐,O
mias29,O
.,O
In,O
a,O
subgroup,O
of,O
patients,O
who,O
had,O
ECGs,O
before,O
and,O
during,O
HCQ,O
treatment,O
.,O
we,O
also,O
assessed,O
the,O
change,O
in,O
QTc30,O
.,O
Secondary,O
outcome,O
variable,O
was,O
time,O
to,O
death,O
or,O
last,O
follow,O
‐,O
up,O
from,O
the,O
starting,O
date,O
of,O
the,O
HCQ,O
treatment,O
.,O
as,O
recorded,O
in,O
the,O
VA,STATE_OR_PROVINCE
vital,O
status,O
files24,O
.25.31,O
.,O
Predictor,O
variables,O
and,O
definitions,O
We,O
ex,O
‐,O
tracted,O
patient,O
demographics,O
.,O
comorbidities,O
.,O
and,O
laboratory,O
data,O
from,O
the,O
VA,STATE_OR_PROVINCE
corporate,O
data,O
warehouse,O
using,O
Structured,O
Query,O
Lan,O
‐,O
guage,O
.,O
The,O
VA,STATE_OR_PROVINCE
corporate,O
data,O
warehouse,O
contains,O
extracts,O
from,O
VA,STATE_OR_PROVINCE
clinical,O
and,O
administrative,O
system,O
that,O
includes,O
complete,O
and,O
other,O
medications,O
were,O
also,O
extracted,O
from,O
the,O
VHA,ORGANIZATION
CDW22,O
.,O
The,O
ECG,O
data,O
were,O
obtained,O
from,O
the,O
Marquette,ORGANIZATION
Universal,ORGANIZATION
System,ORGANIZATION
for,ORGANIZATION
Elec,ORGANIZATION
‐,O
trocardiography,O
database24,O
.25,O
.,O
Chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
(,O
CKD,O
),O
was,O
defined,O
as,O
estimated,O
glomerular,O
filtration,O
rate,O
(,O
eGFR,O
),O
<,O
60,NUMBER
ml,O
/,O
min,DURATION
.,O
The,O
eGFR,O
was,O
calculated,O
with,O
the,O
Cockcroft,O
‐,O
Gault,O
Equation,O
(,O
[,O
140,NUMBER
‐,O
age,O
],O
weight,O
in,O
kg,O
),O
/,O
(,O
serum,O
creatinine,O
72,NUMBER
;,O
multiplied,O
by,O
0.85,NUMBER
in,O
women,O
),O
.,O
Statistical,ORGANIZATION
Analysis,ORGANIZATION
Data,ORGANIZATION
are,O
presented,O
as,O
mean,O
(,O
standard,O
deviation,O
),O
or,O
median,O
(,O
interquartile,O
range,O
),O
for,O
continu,O
‐,O
ous,O
variables,O
.,O
and,O
number,O
(,O
n,O
),O
and,O
percentage,O
(,PERCENT
%,PERCENT
),O
for,O
categorical,O
variables,O
.,O
Comparisons,O
of,O
characteristics,O
among,O
patients,O
with,O
vs.,O
without,O
QTc,O
prolongation,O
were,O
made,O
with,O
chi,O
‐,O
square,O
test,O
or,O
Fish,O
‐,O
ers,O
exact,O
test,O
for,O
categorical,O
variables,O
and,O
unpaired,O
t,O
test,O
for,O
continuous,O
variables,O
.,O
The,O
ECG,O
characteristics,O
before,O
vs.,O
during,O
HCQ,O
therapy,O
were,O
compared,O
using,O
paired,O
t,O
‐,O
test,O
.,O
Independent,RELIGION
pre,O
‐,O
dictors,O
of,O
prolonged,O
QTc,O
were,O
identified,O
by,O
multivariable,O
logis,O
‐,O
tic,O
regression,O
analysis,O
.,O
Survival,O
curves,O
were,O
constructed,O
using,O
the,O
KaplanMeier,O
method,O
and,O
the,O
differences,O
of,O
survival,O
among,O
pa,O
‐,O
tients,O
with,O
vs.,O
without,O
prolonged,O
QTc,O
was,O
examined,O
by,O
the,O
log,O
‐,O
rank,O
test,O
.,O
Cox,O
proportional,O
hazards,O
analysis,O
was,O
used,O
to,O
assess,O
the,O
association,O
between,O
QTc,O
prolongation,O
and,O
mortality,O
.,O
and,O
to,O
calculate,O
the,O
hazard,O
ratio,O
(,O
HR,DURATION
),O
and,O
95,PERCENT
%,PERCENT
confidence,O
interval,O
(,O
CI,O
),O
.,O
Statistical,O
analyses,O
were,O
performed,O
with,O
IBM,ORGANIZATION
SPSS,O
(,O
version,O
25,NUMBER
;,O
IBM,ORGANIZATION
Corp,ORGANIZATION
.,O
Armonk,LOCATION
.,O
NY,STATE_OR_PROVINCE
.,O
Patient,O
characteristics,O
64.0,NUMBER
(,O
10.9,NUMBER
),O
years,DURATION
and,O
734,NUMBER
(,O
90,PERCENT
%,PERCENT
),O
of,O
the,O
patients,O
were,O
male,O
.,O
Cardiovascular,O
comor,O
‐,O
bidities,O
included,O
hypertension,CAUSE_OF_DEATH
(,O
n,O
=,O
532,NUMBER
.,O
65,PERCENT
%,PERCENT
),O
.,O
coronary,O
artery,O
dis,O
‐,O
ease,O
(,O
n,O
=,O
234,NUMBER
.,O
29,PERCENT
%,PERCENT
),O
.,O
diabetes,CAUSE_OF_DEATH
(,O
n,O
=,O
202,NUMBER
.,O
25,PERCENT
%,PERCENT
),O
and,O
heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
(,O
n,O
=,O
65,NUMBER
.,O
8,PERCENT
%,PERCENT
),O
.,O
A,O
total,O
of,O
99,NUMBER
(,O
12,PERCENT
%,PERCENT
),O
patients,O
had,O
chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
Hy,O
‐,O
droxychloroquine,O
was,O
prescribed,O
to,O
treat,O
systemic,O
lupus,O
erhythe,O
‐,O
matosus,O
in,O
786,NUMBER
(,O
96,PERCENT
%,PERCENT
),O
of,O
the,O
patients,O
at,O
a,O
median,O
starting,O
dosage,O
of,O
400,NUMBER
mg,O
daily,SET
.,O
The,O
median,O
(,O
25th,ORDINAL
‐,O
75th,ORDINAL
percentile,O
),O
duration,O
of,O
HCQ,O
therapy,O
was,O
1006,DATE
(,O
471,NUMBER
‐,O
2075,DATE
),O
days,DURATION
.,O
ECG,O
characteristics,O
during,O
HCQ,O
treatment,O
A,O
12,NUMBER
‐,O
lead,O
ECG,O
was,O
performed,O
234,NUMBER
(,O
92,NUMBER
‐,O
586,NUMBER
),O
days,DURATION
after,O
starting,O
HCQ,O
therapy,O
in,O
all,O
study,O
rate,O
was,O
74.8,NUMBER
(,O
17.3,NUMBER
),O
beats,O
/,O
min,DURATION
.,O
The,O
mean,O
on,O
‐,O
treatment,O
QTc,O
.,O
based,O
on,O
Bazett,O
formula,O
.,O
was,O
430.9,NUMBER
(,O
31.8,NUMBER
),O
msec,O
.,O
A,O
total,O
of,O
55,NUMBER
(,O
7,PERCENT
%,PERCENT
),O
patients,O
had,O
on,O
‐,O
treatment,O
QTc,O
470,NUMBER
‐,O
500,NUMBER
msec,O
.,O
and,O
12,NUMBER
prolonged,O
QTc,O
were,O
older,O
and,O
more,O
likely,O
to,O
have,O
CKD,O
.,O
history,O
of,O
atrial,O
fibrillation,O
and,O
history,O
of,O
predic,O
‐,O
tors,O
of,O
QTc,O
>,O
470,NUMBER
msec,O
.,O
Notably,O
.,O
the,O
odds,O
of,O
QTc,O
prolongation,O
was,O
>,O
5,NUMBER
times,O
higher,O
(,O
OR,O
5.1,NUMBER
;,O
95,PERCENT
%,PERCENT
CI,O
1.23,NUMBER
‐,O
21.1,NUMBER
;,O
p,O
=,O
0.025,NUMBER
),O
when,O
eGFR,O
was,O
<,O
30,NUMBER
ml,O
/,O
min,DURATION
.,O
There,O
was,O
a,O
negative,O
correlation,O
Paired,O
ECG,O
before,O
and,O
during,O
HCQ,O
treatment,O
A,O
total,O
of,O
591,NUMBER
(,O
72,PERCENT
%,PERCENT
),O
patients,O
had,O
ECGs,O
performed,O
before,O
(,O
median,O
345,NUMBER
[,O
98,NUMBER
‐,O
833,NUMBER
],O
days,DURATION
),O
and,O
after,O
(,O
median,O
204,NUMBER
[,O
84,NUMBER
‐,O
489,NUMBER
],O
days,DURATION
),O
starting,O
the,O
HCQ,O
treatment,O
.,O
On,O
these,O
paired,O
ECGs,O
.,O
there,O
was,O
a,O
modest,O
prolongation,O
of,O
QTc,O
from,O
424.4,NUMBER
(,O
29.7,NUMBER
),O
msec,O
.,O
to,O
432.0,NUMBER
(,O
32.3,NUMBER
),O
msec,O
.,O
(,O
p,O
<,O
0.0001,NUMBER
),O
QTc,O
or,O
a,O
QTc,O
>,O
500,NUMBER
msec,O
with,O
HCQ,O
treatment,O
.,O
These,O
patients,O
were,O
more,O
likely,O
to,O
have,O
chronic,O
kidney,O
disease,CAUSE_OF_DEATH
(,O
44,PERCENT
%,PERCENT
vs.,O
14,PERCENT
%,PERCENT
;,O
p,O
=,O
0.0001,NUMBER
),O
than,O
the,O
rest,O
of,O
the,O
cohort,O
with,O
paired,O
ECGs,O
.,O
Survival,O
in,O
relation,O
to,O
QTc,O
Of,O
the,O
819,NUMBER
patients,O
in,O
the,O
whole,O
study,O
cohort,O
.,O
269,NUMBER
(,O
33,PERCENT
%,PERCENT
),O
died,O
over,O
a,O
median,O
5.97,NUMBER
(,O
3.3310.11,NUMBER
),O
years,DURATION
of,O
follow,O
up,O
.,O
In,O
comparison,O
to,O
those,O
who,O
sur,O
‐,O
vived,O
.,O
the,O
patients,O
who,O
died,O
were,O
older,O
.,O
more,O
likely,O
to,O
be,O
men,O
and,O
more,O
likely,O
to,O
have,O
coronary,O
disease,CAUSE_OF_DEATH
.,O
heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
and,O
CKD,O
.,O
In,O
univariable,O
Cox,O
regression,O
analysis,O
.,O
QTc,O
>,O
470,NUMBER
msec,O
.,O
during,O
HCQ,O
therapy,O
was,O
associated,O
with,O
adjustment,O
for,O
age,O
.,O
sex,O
.,O
and,O
co,O
‐,O
morbidities,O
QTc,O
>,O
470,NUMBER
msec,O
.,O
during,O
HCQ,O
treatment,O
was,O
no,O
longer,O
associated,O
with,O
long,O
‐,O
term,O
mortality,O
.,O
In,O
patients,O
with,O
paired,O
ECG,O
.,O
delta,O
QTc,O
was,O
not,O
associated,O
with,O
mortality,O
(,O
HR,DURATION
1.001,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
0.998,NUMBER
‐,O
1.005,NUMBER
;,O
p,O
=,O
0.51,NUMBER
),O
.,O
This,O
investigation,O
showed,O
that,O
a,O
signifi,O
‐,O
cant,O
fraction,O
(,O
8.3,PERCENT
%,PERCENT
),O
of,O
the,O
patients,O
prescribed,O
HCQ,O
for,O
the,O
treatment,O
of,O
SLE,O
had,O
QTc,O
>,O
470,NUMBER
msec,O
on,O
ECG,O
.,O
including,O
1.5,PERCENT
%,PERCENT
who,O
had,O
QTc,O
>,O
500,NUMBER
msec,O
.,O
Chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
atrial,O
fibrillation,O
and,O
heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
were,O
associated,O
with,O
QTc,O
prolongation,O
.,O
Among,O
patients,O
with,O
ECGs,MISC
performed,O
both,O
before,O
and,O
during,O
treatment,O
.,O
HCQ,O
had,O
a,O
modest,O
effect,O
on,O
QTc,O
(,O
mean,O
increase,O
8,NUMBER
msec,O
),O
except,O
in,O
3.4,PERCENT
%,PERCENT
of,O
the,O
patients,O
who,O
had,O
>,O
15,PERCENT
%,PERCENT
increase,O
in,O
QTc,O
.,O
The,O
QTc,O
in,O
‐,O
terval,O
during,O
HCQ,O
treatment,O
was,O
associated,O
with,O
long,O
‐,O
term,O
sur,O
‐,O
vival,O
in,O
univariable,O
analysis,O
.,O
while,O
the,O
change,O
in,O
QTc,O
was,O
not,O
.,O
Hydroxychloroquine,O
blocks,O
the,O
KCNH2,O
‐,O
encoded,O
hERG,O
/,O
Kv11,O
.1,NUMBER
potassium,O
channel,O
and,O
can,O
contribute,O
to,O
prolongation,O
of,O
the,O
QTc,O
interval12,O
.,O
Mutations,O
involving,O
these,O
potassium,O
channels,O
cause,O
the,O
long,O
QT,O
syndrome,O
and,O
their,O
blockage,O
by,O
certain,O
drugs,CRIMINAL_CHARGE
can,O
be,O
associated,O
with,O
QT,O
prolongation,O
.,O
torsade,O
de,O
pointes,O
.,O
and,O
sudden,O
death,O
.,O
While,O
QT,O
prolongation,O
and,O
postings,O
on,O
the,O
FDA,ORGANIZATION
Adverse,O
Events,O
Reporting,O
System7,O
.8.10,O
.,O
A,O
retrospective,O
study,O
of,O
112,NUMBER
patients,O
with,O
SLE,O
treated,O
with,O
HCQ,O
reported,O
that,O
cardiac,O
conduction,O
abnormalities,O
were,O
present,DATE
in,O
18,PERCENT
%,PERCENT
of,O
the,O
subjects,O
.,O
These,O
included,O
incomplete,O
bundle,O
branch,O
blocks,O
and,O
second,ORDINAL
and,ORDINAL
third,ORDINAL
degree,O
atrioventricular,O
blocks,O
.,O
The,O
presence,O
of,O
conduction,O
abnormalities,O
were,O
not,O
associ,O
‐,O
ated,O
with,O
mortality,O
during,O
the,DURATION
first,DURATION
10,DURATION
years,DURATION
of,O
follow,O
‐,O
up,O
but,O
thereafter,O
.,O
subjects,O
with,O
cardiac,O
conduction,O
abnormalities,O
had,O
a,O
higher,O
risk,O
of,O
death33,O
.,O
In,O
a,O
larger,O
series,O
of,O
453,NUMBER
consecutive,O
SLE,O
patients,O
.,O
84,PERCENT
%,PERCENT
of,O
whom,O
were,O
taking,O
HCQ,O
.,O
16,PERCENT
%,PERCENT
had,O
cardiac,O
conduction,O
abnormalities34,O
.,O
Since,O
were,O
not,O
able,O
to,O
attribute,O
them,O
directly,O
to,O
the,O
use,O
of,O
HCQ,O
.,O
In,O
fact,O
.,O
higher,O
cumulative,O
doses,O
of,O
HCQ,O
were,O
associated,O
with,O
fewer,O
conduction,O
abnormalities,O
.,O
QTc,O
prolongation,O
was,O
rare,O
and,O
only,O
the,O
incidence,O
of,O
conduction,O
delays,O
and,O
QT,O
pro,O
‐,O
longation,O
was,O
similar,O
to,O
what,O
is,O
expected,O
in,O
the,O
general,TITLE
pub,O
‐,O
lic35,O
.,O
There,O
are,O
currently,DATE
more,O
than,O
7.15,MONEY
million,MONEY
confirmed,O
cased,O
of,O
COVID,O
‐,O
19,NUMBER
world,O
‐,O
wide,O
.,O
Initially,O
.,O
HCQ,O
has,O
emerged,O
as,O
a,O
potential,O
therapy,O
for,O
COVID,O
‐,O
19,NUMBER
given,O
in,O
vitro,O
evidence,O
of,O
antivi,O
‐,O
ral,O
properties11,O
.36,O
.,O
Guidelines,O
quickly,O
emerged,O
cautioning,O
the,O
use,O
of,O
the,O
medication,O
in,O
the,O
arrhythmic,O
toxicity,O
risk,O
of,O
HCQ,O
is,O
likely,O
low,O
given,O
the,O
relatively,O
short,O
duration,O
of,O
treatment,O
for,O
COVID,O
‐,O
1937,DATE
.,O
They,O
recommend,O
using,O
caution,O
in,O
patients,O
with,O
known,O
congenital,O
long,O
QT,O
syndrome,O
.,O
renal,O
insufficiency,O
.,O
on,O
QT,O
prolong,O
‐,O
ing,O
medications,O
(,O
e.g.,O
certain,O
antiarrhythmics,O
.,O
antipsychotics,O
.,O
antifungals,O
.,O
and,O
macrolide,O
antibiotics,O
such,O
as,O
azithromycin,O
),O
.,O
or,O
with,O
electrolyte,O
caution,O
when,O
using,O
HCQ,O
+,O
/,O
‐,O
azithromycin,O
in,O
any,O
patient,O
with,O
a,O
prolonged,O
QTc,O
>,O
470msec,NUMBER
in,O
males,O
and,O
>,O
480,NUMBER
msec,O
in,O
females12,O
.,O
Most,O
recently,DATE
.,O
a,O
small,O
randomized,O
controlled,O
trial,O
and,O
several,O
observational,O
studies,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
treated,O
with,O
HCQ,O
showed,O
no,O
evidence,O
of,O
benefit,O
and,O
some,O
concerning,O
trends,O
for,O
harm1417,NUMBER
.40,O
.,O
At,O
this,O
moment,O
.,O
the,O
FDA,ORGANIZATION
has,O
removed,O
the,O
combination,O
with,O
azithromycin,O
.,O
except,O
in,O
the,O
context,O
of,O
a,O
clinical,O
trial41,O
.,O
However,O
.,O
despite,O
the,O
negative,O
trials,O
the,O
medication,O
has,O
received,O
significant,O
media,O
attention,O
and,O
it,O
remains,O
possible,O
that,O
a,O
sig,O
‐,O
nificant,O
portion,O
of,O
the,O
population,O
is,O
exposed,O
to,O
the,O
medication,O
.,O
The,O
association,O
of,O
impaired,O
kidney,O
function,O
with,O
QTc,O
prolongation,O
is,O
especially,O
concerning,O
since,O
reports,O
from,O
China,COUNTRY
indicate,O
that,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
are,O
more,O
likely,O
to,O
experience,O
renal,O
dys,O
‐,O
function42,O
.,O
Given,O
the,O
higher,O
co,O
‐,O
morbidity,O
burden,O
and,O
acuity,O
of,O
patients,O
hospitalized,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
it,O
is,O
possible,O
that,O
a,O
higher,O
percentage,O
would,O
exhibit,O
QTc,O
prolongation,O
with,O
HCQ,O
treatment,O
.,O
The,O
current,DATE
report,O
provides,O
contemporary,O
information,O
on,O
the,O
ef,O
‐,O
fect,O
of,O
HCQ,O
on,O
QTc,O
to,O
support,O
the,O
above,O
recommendations,O
.,O
While,O
the,O
additional,O
prolongation,O
of,O
QTc,O
with,O
HCQ,O
was,O
in,O
general,TITLE
mod,O
‐,O
est,O
.,O
substantial,O
prolongation,O
occurred,O
in,O
3.2,PERCENT
%,PERCENT
of,O
the,O
patients,O
.,O
Guidelines,O
for,O
performing,O
screening,O
ECGs,O
and,O
recommendations,O
for,O
monitoring,O
patients,O
started,O
on,O
HCQ,O
have,O
been,O
proposed18,O
.43,O
.,O
Therefore,O
.,O
it,O
is,O
prudent,O
to,O
check,O
a,O
baseline,O
ECG,O
prior,O
to,O
initi,O
‐,O
ating,O
therapy,O
.,O
avoid,O
hypokalemia,O
and,O
monitor,O
patients,O
with,O
im,O
‐,O
paired,O
kidney,O
function,O
and,O
those,O
taking,O
other,O
QT,O
prolonging,O
medi,O
‐,O
cations,O
closely38,O
.39,O
.,O
Although,O
this,O
study,O
did,O
not,O
include,O
genetic,O
data,O
.,O
extra,O
precautions,O
are,O
also,O
recommended,O
in,O
patients,O
with,O
congenital,O
long,O
QT,O
syndrome,O
.,O
This,O
study,O
showed,O
that,O
1.5,PERCENT
%,PERCENT
of,O
pa,O
‐,O
tients,O
taking,O
HCQ,O
had,O
QTc,O
>,O
500,NUMBER
msec,O
.,O
Class,O
III,O
antiarrhythmic,O
medications,O
dofetilide,O
and,O
sotalol,O
.,O
used,O
for,O
the,O
treatment,O
atrial,O
fibrillation,O
.,O
can,O
also,O
cause,O
QT,O
prolongation,O
.,O
In,O
the,O
DIAMOND,O
‐,O
CHF,O
study,O
.,O
dofetilide,O
was,O
discontinued,O
in,O
2,PERCENT
%,PERCENT
of,O
the,O
patients,O
for,O
QT,O
prolongation44,O
.,O
However,O
.,O
more,O
recent,O
data,O
from,O
general,TITLE
practice,O
showed,O
that,O
dofetilide,O
was,O
discontinued,O
in,O
up,O
to,O
17,PERCENT
%,PERCENT
of,O
patients,O
due,O
to,O
QT,O
prolongation38,O
.,O
Sotalol,PERSON
.,O
on,O
the,O
other,O
hand,O
.,O
was,O
discon,O
‐,O
tinued,O
in,O
4.3,PERCENT
%,PERCENT
of,O
patients,O
due,O
to,O
prolonged,O
QT,O
interval45,O
.,O
The,O
results,O
of,O
the,O
current,DATE
study,O
should,O
be,O
evaluated,O
within,O
this,O
con,O
‐,O
text,O
.,O
We,O
acknowledge,O
the,O
limitations,O
of,O
this,O
study,O
.,O
There,O
may,O
be,O
a,O
selection,O
bias,O
for,O
patients,O
who,O
had,O
ECGs,O
while,O
on,O
therapy,O
.,O
Pa,STATE_OR_PROVINCE
‐,O
tients,O
with,O
SLE,O
are,O
different,O
from,O
ill,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
who,O
are,O
likely,O
to,O
have,O
a,O
higher,O
burden,O
of,O
cardiovascular,O
comorbidi,O
‐,O
ties,O
and,O
impaired,O
kidney,O
function,O
making,O
them,O
more,O
vulnerable,O
to,O
the,O
adverse,O
effects,O
of,O
HCQ,O
.,O
Further,O
.,O
HCQ,O
has,O
a,O
long,O
half,O
‐,O
life,O
.,O
Steady,O
state,O
is,O
achieved,O
after,O
3,NUMBER
‐,O
4,DURATION
months,DURATION
of,O
therapy46,O
.,O
The,O
aver,O
‐,O
age,O
time,O
on,O
HCQ,O
at,O
the,O
time,DATE
the,O
ECG,O
was,O
performed,O
in,O
this,O
study,O
was,O
237,NUMBER
(,O
92,NUMBER
‐,O
575,NUMBER
),O
days,DURATION
suggesting,O
that,O
steady,O
state,O
had,O
been,O
achieved,O
.,O
However,O
.,O
patients,O
treated,O
for,O
COVID,O
‐,O
19,NUMBER
are,O
likely,O
to,O
receive,O
shorter,O
courses,O
of,O
therapy,O
and,O
this,O
study,O
can,O
not,O
address,O
expected,O
ECG,O
changes,O
in,O
this,O
timeframe,O
.,O
Finally,O
.,O
this,O
study,O
was,O
retrospective,O
.,O
lacked,O
genetic,O
diagnostics,O
and,O
largely,O
consisted,O
of,O
men,O
.,O
Hydroxychloroquine,O
therapy,O
is,O
associated,O
with,O
QT,O
prolon,O
‐,O
gation,O
in,O
a,O
significant,O
fraction,O
of,O
patients,O
who,O
were,O
on,O
chronic,O
therapy,O
with,O
this,O
medication,O
for,O
SLE,O
.,O
While,O
recent,O
trials,O
have,O
not,O
supported,O
the,O
expansion,O
of,O
HCQ,O
use,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
it,O
has,O
raised,O
significant,O
concerns,O
with,O
QT,O
prolongation,O
and,O
arrhythmo,O
‐,O
genic,O
risk,O
.,O
Avoiding,O
hypokalemia,O
and,O
carefully,O
monitoring,O
of,O
QTc,O
are,O
warranted,O
;,O
particularly,O
in,O
those,O
with,O
impaired,O
kidney,O
func,O
‐,O
tion,O
and,O
those,O
receiving,O
other,O
QT,O
prolonging,O
drugs,CRIMINAL_CHARGE
.,O
COVID,O
‐,O
19,NUMBER
Dashboard,O
by,O
the,O
Center,ORGANIZATION
for,ORGANIZATION
Systems,ORGANIZATION
Science,ORGANIZATION
and,ORGANIZATION
Engineering,ORGANIZATION
(,O
CSSE,O
),O
at,O
Wu,O
Z,O
.,O
McGoogan,PERSON
JM,O
:,O
Characteristics,O
of,O
and,O
Important,O
Lessons,O
From,O
the,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
Outbreak,O
in,O
China,COUNTRY
.,O
JAMA,O
[,O
Internet,MISC
],O
2020,DATE
;,O
323:1239,NUMBER
.,O
Available,O
Madjid,O
M,O
.,O
Safavi,PERSON
‐,O
Naeini,O
P,O
.,O
Solomon,ORGANIZATION
SD,ORGANIZATION
.,O
Vardeny,O
O,O
:,O
Potential,O
Effects,O
of,O
Coronaviruses,MISC
on,O
the,O
Cardiovascular,O
System,O
.,O
JAMA,O
Cardiol,O
[,O
Inter,O
‐,O
net,O
],O
2020,DATE
;,O
.,O
Available,O
from,O
:,O
Fried,O
JA,O
.,O
Ramasubbu,PERSON
K,PERSON
.,O
Bhatt,PERSON
R,O
.,O
et,O
al.,O
:,O
The,O
Variety,O
of,O
Cardiovascular,O
Presentations,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Circulation,O
[,O
Internet,MISC
],O
Ovid,ORGANIZATION
Technologies,ORGANIZATION
(,O
Wolters,ORGANIZATION
Kluwer,ORGANIZATION
Health,ORGANIZATION
),O
.,O
2020,DATE
;,O
141:19301936,NUMBER
.,O
Available,O
from,O
:,O
Vardeny,O
O,O
.,O
Madjid,PERSON
M,O
.,O
Solomon,PERSON
SD,STATE_OR_PROVINCE
:,O
Applying,O
the,O
Lessons,O
of,O
Influenza,CAUSE_OF_DEATH
to,O
COVID,O
‐,O
19,NUMBER
During,O
a,O
Time,O
of,O
Uncertainty,O
.,O
Circulation,O
[,O
Internet,MISC
],O
2020,DATE
;,O
141:16671669,NUMBER
.,O
Avail,O
‐,O
able,O
from,O
:,O
U.S,ORGANIZATION
Food,ORGANIZATION
&,ORGANIZATION
Drug,ORGANIZATION
Administration,ORGANIZATION
[,O
Internet,MISC
],O
.,O
Available,O
from,O
:,O
Morgan,ORGANIZATION
ND,ORGANIZATION
.,O
Patel,PERSON
S,O
V.,O
.,O
Dvorkina,PERSON
O,O
:,O
Suspected,O
Hydroxychloro,O
‐,O
quine,O
‐,O
Associated,O
QTInterval,O
Prolongation,O
in,O
a,O
Patient,O
With,O
Sys,O
‐,O
temic,O
Lupus,CAUSE_OF_DEATH
Erythematosus,CAUSE_OF_DEATH
.,O
J,PERSON
Clin,PERSON
Rheumatol,PERSON
[,O
Internet,MISC
],O
2013,DATE
;,O
19:286288,NUMBER
.,O
Available,O
from,O
:,O
OLaughlin,O
JP,O
.,O
Mehta,ORGANIZATION
PH,ORGANIZATION
.,O
Wong,PERSON
BC,STATE_OR_PROVINCE
:,O
Life,O
Threatening,O
Severe,O
QTc,O
Prolongation,O
in,O
Patient,O
with,O
Systemic,O
Lu,PERSON
‐,PERSON
pus,O
Erythematosus,O
due,O
to,O
Hydroxychloroquine,PERSON
.,O
Case,O
Reports,O
Cardiol,PERSON
[,O
Internet,MISC
],O
2016,DATE
;,O
2016:14,NUMBER
.,O
Available,O
from,O
:,O
Chen,PERSON
C,O
‐,O
Y,O
.,O
Wang,PERSON
F,O
‐,O
L,O
.,O
Lin,PERSON
C,O
‐,O
C,O
:,O
Chronic,O
Hydroxychloroquine,O
Use,O
Associated,O
with,O
QT,O
Prolonga,O
‐,O
tion,O
and,O
Refractory,O
Ventricular,O
Arrhythmia,O
.,O
Clin,O
Toxicol,O
[,O
Inter,O
‐,O
net,O
],O
2006,DATE
;,O
44:173,NUMBER
FDA,O
Adverse,O
Events,O
Reporting,O
System,O
(,O
FAERS,O
),O
Public,O
Dashboard,MISC
[,MISC
Internet,MISC
],O
.,O
[,O
cited,O
2020,DATE
Yao,PERSON
X,PERSON
.,O
Ye,PERSON
F,PERSON
.,O
Zhang,O
M,O
.,O
et,O
al.,O
:,O
In,O
Vitro,O
Antiviral,O
Activity,O
and,O
Projection,O
of,O
Optimized,O
Dos,O
‐,O
ing,O
Design,O
of,O
Hydroxychloroquine,LOCATION
for,O
the,O
Treatment,O
of,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
Clin,O
In,O
‐,O
fect,O
Dis,O
[,O
Internet,MISC
],O
2020,DATE
;,O
.,O
Available,O
from,O
:,O
Giudicessi,PERSON
JR,PERSON
.,O
Nose,O
‐,O
worthy,O
PA,STATE_OR_PROVINCE
.,O
Friedman,ORGANIZATION
PA,ORGANIZATION
.,O
Ackerman,PERSON
MJ,O
:,O
Urgent,O
Guidance,O
for,O
Navigat,O
‐,O
ing,O
and,O
Circumventing,O
the,O
QTc,O
‐,O
Prolonging,O
and,O
Torsadogenic,O
Poten,O
‐,O
tial,O
of,O
Possible,O
Pharmacotherapies,O
for,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
19,NUMBER
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
Mayo,O
Clin,O
Proc,O
[,O
Internet,MISC
],O
Elsevier,O
.,O
2020,DATE
[,O
cited,O
2020,DATE
Apr,DATE
19,DATE
],O
;,O
95:12131221,NUMBER
.,O
Available,O
from,O
:,O
or,O
Hydroxychloroquine,O
Sul,O
‐,O
fate,O
Supplied,O
From,O
the,O
Strategic,O
National,O
Stockpile,O
for,O
Treatment,O
of,O
2019,DATE
Coronavirus,O
Disease,CAUSE_OF_DEATH
.,O
2020,DATE
.,O
.,O
Tang,O
W,O
.,O
Cao,PERSON
Z,PERSON
.,O
Han,O
M,O
.,O
et,O
al.,O
:,O
Hydroxychloroquine,O
in,O
patients,O
with,O
mainly,O
mild,O
to,O
moderate,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
:,O
open,O
label,O
.,O
randomised,O
controlled,O
tri,O
‐,O
al,O
.,O
BMJ,O
[,O
Internet,MISC
],O
2020,DATE
;,O
369,NUMBER
:,O
m1849,O
.,O
Available,O
from,O
:,O
Mahvas,O
M,O
.,O
Tran,MISC
V,O
‐,O
T,O
.,O
Roumier,PERSON
M,O
.,O
et,O
al.,O
:,O
Clinical,O
efficacy,O
of,O
hydroxychloro,O
‐,O
quine,O
in,O
patients,O
with,O
covid,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
who,O
require,O
oxygen,O
:,O
ob,O
‐,O
servational,O
comparative,O
study,O
using,O
routine,O
care,O
data,O
.,O
BMJ,O
[,O
In,O
‐,O
ternet,O
],O
2020,DATE
;,O
369,NUMBER
:,O
m1844,O
.,O
Available,O
from,O
:,O
Geleris,PERSON
J,PERSON
.,O
Sun,O
Y,O
.,O
Platt,PERSON
J,O
.,O
Zucker,PERSON
J,PERSON
.,O
Baldwin,PERSON
M,O
.,O
Hripcsak,PERSON
G,PERSON
.,O
Labella,PERSON
A,O
.,O
Manson,ORGANIZATION
DK,ORGANIZATION
.,O
Kubin,PERSON
C,O
.,O
Barr,PERSON
RG,PERSON
.,O
Sobieszczyk,PERSON
ME,STATE_OR_PROVINCE
.,O
Schluger,O
NW,O
:,O
Observational,O
Study,O
of,O
Hydroxychloroquine,O
in,O
Hospitalized,O
Patients,O
with,O
Covid,O
‐,O
19,NUMBER
.,O
N,O
Engl,O
J,O
Med,MISC
[,MISC
Internet,MISC
],O
2020,DATE
;,O
382:24112418,NUMBER
.,O
Magagnoli,PERSON
J,PERSON
.,O
Narendran,PERSON
S,PERSON
.,O
Pereira,PERSON
F,O
.,O
Cummings,ORGANIZATION
TH,ORGANIZATION
.,O
Hardin,PERSON
JW,PERSON
.,O
Sutton,PERSON
SS,O
.,O
Ambati,PERSON
J,O
:,O
Outcomes,O
of,O
hydroxychloroquine,O
usage,O
in,O
United,COUNTRY
States,COUNTRY
veterans,O
hospital,O
‐,O
ized,O
with,O
Mitra,ORGANIZATION
RL,ORGANIZATION
.,O
Greenstein,ORGANIZATION
SA,ORGANIZATION
.,O
Epstein,PERSON
LM,O
:,O
An,O
algorithm,O
for,O
managing,O
QT,O
prolongation,O
in,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
patients,O
treated,O
with,O
either,O
chloroquine,O
or,O
hydroxychloroquine,O
in,O
conjunction,O
with,O
azithromycin,O
:,O
Possible,O
benefits,O
of,O
intravenous,O
lidocaine,O
.,O
Hear,MISC
Case,MISC
Reports,MISC
[,MISC
Internet,MISC
],O
2020,DATE
;,O
6:244248,NUMBER
.,O
Available,O
from,O
:,O
Szekely,O
Y,O
.,O
Lichter,O
Y,O
.,O
Shrkihe,ORGANIZATION
BA,ORGANIZATION
.,O
Bruck,PERSON
H,O
.,O
Oster,PERSON
HS,O
.,O
Viskin,PERSON
S,O
:,O
Chloroquine,O
‐,O
induced,O
torsades,O
de,O
pointes,O
in,O
a,O
patient,O
with,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
.,O
Hear,MISC
Rhythm,MISC
[,MISC
Internet,MISC
],O
2020,DATE
;,O
S1547,O
‐,O
5271,DATE
(,O
20,NUMBER
),O
:,O
304203,NUMBER
.,O
Available,O
from,O
:,O
Jankelson,PERSON
L,O
.,O
Karam,PERSON
G,PERSON
.,O
Becker,PERSON
ML,O
.,O
Chinitz,ORGANIZATION
LA,ORGANIZATION
.,O
Tsai,PERSON
M,O
‐,O
C,O
:,O
QT,O
prolongation,O
.,O
torsades,O
de,O
pointes,O
.,O
and,O
sudden,O
death,O
with,O
short,O
courses,O
of,O
chloroquine,O
or,O
hydroxychloroquine,O
as,O
Chorin,O
E,O
.,O
Wadhwani,PERSON
L,O
.,O
Magnani,PERSON
S,O
.,O
et,O
al.,O
:,O
QT,O
interval,O
prolongation,O
and,O
torsade,O
de,O
pointes,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
treated,O
with,O
hydroxychloroquine,O
/,O
azithromycin,O
.,O
Hear,O
Rhythm,O
[,O
Internet,MISC
],O
2020,DATE
;,O
S1547,O
‐,O
5271,DATE
(,O
20,NUMBER
),O
:,O
304355,NUMBER
.,O
Available,O
from,O
:,O
Rector,PERSON
TS,PERSON
.,O
Adabag,O
S,O
.,O
Cunningham,PERSON
F,O
.,O
Nelson,PERSON
D,O
.,O
Dieperink,PERSON
E,O
:,O
Out,O
‐,O
comes,O
of,O
Citalopram,ORGANIZATION
Dosage,ORGANIZATION
Risk,ORGANIZATION
Mitigation,ORGANIZATION
in,O
a,O
Veteran,O
Popula,O
‐,O
tion,O
.,O
Am,O
J,O
Psychiatry,O
[,O
Internet,MISC
],O
2016,DATE
;,O
173:896902,NUMBER
.,O
Available,O
from,O
:,O
Westermeyer,PERSON
J,PERSON
.,O
Adabag,O
S,O
.,O
Anand,PERSON
V,PERSON
.,O
Thuras,O
P,O
.,O
Yoon,PERSON
G,PERSON
.,O
Batres,PERSON
‐,O
y,O
‐,O
Carr,PERSON
T,O
:,O
Methadone,CAUSE_OF_DEATH
maintenance,O
dose,O
/,O
weight,O
ratio,O
.,O
long,O
QTc,O
.,O
and,O
EKG,O
screening,O
.,O
Am,O
J,O
Addict,O
[,O
Internet,MISC
],O
Moulki,O
N,O
.,O
Kealhofer,PERSON
J,PERSON
V.,PERSON
.,O
Benditt,PERSON
DG,PERSON
.,O
Gravely,MISC
A,MISC
.,O
Vakil,PERSON
K,PERSON
.,O
Garcia,PERSON
S,O
.,O
Adabag,O
S,O
:,O
and,O
prolonged,O
PR,STATE_OR_PROVINCE
interval,O
on,O
electrocardiogram,O
.,O
J,PERSON
Interv,PERSON
Card,PERSON
Electrophysiol,PERSON
[,O
Internet,MISC
],O
Coumbe,ORGANIZATION
AG,ORGANIZATION
.,O
Naksuk,PERSON
N,PERSON
.,O
Newell,ORGANIZATION
MC,ORGANIZATION
.,O
Somasundaram,O
PE,STATE_OR_PROVINCE
.,O
Ben,PERSON
‐,PERSON
ditt,O
DG,O
.,O
Adabag,O
S,O
:,O
Longterm,O
follow,O
‐,O
up,O
of,O
older,O
patients,O
with,O
Mob,O
‐,O
itz,O
type,O
I,DURATION
second,DURATION
degree,O
atrioventricular,O
block,O
.,O
Heart,O
[,O
Inter,O
‐,O
net,O
],O
2013,DATE
;,O
99:334338,NUMBER
.,O
Available,O
from,O
:,O
Bogossian,O
H,O
.,O
Frommeyer,O
G,O
.,O
Ninios,MISC
I,O
.,O
et,O
al.,O
:,O
New,O
formula,O
for,O
evaluation,O
of,O
the,O
QT,O
interval,O
in,O
patients,O
with,O
left,O
bundle,O
branch,O
block,O
.,O
Hear,MISC
Rhythm,MISC
[,MISC
Internet,MISC
],O
2014,DATE
;,O
11:22732277,NUMBER
.,O
Al,O
‐,O
Khatib,O
SM,O
.,O
LaPointe,ORGANIZATION
NMA,ORGANIZATION
.,O
Kramer,PERSON
JM,O
.,O
Califf,PERSON
RM,O
:,O
What,O
Clinicians,O
Should,O
Know,O
About,O
the,O
QT,O
Interval,O
.,O
JAMA,O
[,O
In,O
‐,O
ternet,O
],O
2003,DATE
;,O
289:21202127,NUMBER
.,O
Available,O
from,O
:,O
Mason,ORGANIZATION
JW,ORGANIZATION
.,O
Ramseth,PERSON
DJ,PERSON
.,O
Chanter,O
DO,O
.,O
Moon,PERSON
TE,PERSON
.,O
Goodman,ORGANIZATION
DB,ORGANIZATION
.,O
Mendzelevski,PERSON
B,O
:,O
Electrocardio,O
‐,O
graphic,O
reference,O
ranges,O
derived,O
from,O
79.743,NUMBER
ambulatory,O
subjects,O
.,O
J,O
Electrocardiol,MISC
[,MISC
Internet,MISC
],O
Churchill,PERSON
Livingstone,PERSON
.,O
2007,DATE
[,O
cited,O
2020,DATE
Apr,DATE
19,DATE
],O
;,O
40:228,NUMBER
‐,O
234,NUMBER
.,O
e8,O
.,O
Available,O
from,O
:,O
Issa,PERSON
Z,PERSON
.,O
Miller,PERSON
J,O
:,O
Clinical,O
Arrhythmology,O
and,O
Electrophysiology,O
:,O
A,O
Companion,TITLE
to,O
Braunwalds,O
Heart,CAUSE_OF_DEATH
Disease,CAUSE_OF_DEATH
.,O
3rd,ORDINAL
Editio,O
.,O
Elsevier,O
.,O
2018,DATE
.,O
.,O
Bart,PERSON
G,PERSON
.,O
Wyman,PERSON
Z,PERSON
.,O
Wang,PERSON
Q,O
.,O
Hodges,PERSON
JS,O
.,O
Karim,PERSON
R,PERSON
.,O
Bart,PERSON
BA,O
:,O
Methadone,CAUSE_OF_DEATH
and,O
the,O
QTc,O
Interval,O
.,O
J,O
Addict,O
Med,O
[,O
Internet,MISC
],O
2017,DATE
;,O
11:489493,NUMBER
.,O
Available,O
from,O
:,O
Jain,PERSON
R,PERSON
.,O
Duval,PERSON
S,O
.,O
Adabag,O
S,O
:,O
How,O
Accurate,O
Is,O
the,O
Eyeball,O
Test,O
?,O
:,O
A,O
Comparison,O
of,O
Physicians,O
Subjective,O
Assessment,O
Versus,O
Statistical,O
Methods,O
in,O
Estimating,O
Mortality,O
Risk,O
After,O
Cardiac,O
Surgery,CAUSE_OF_DEATH
.,O
Circ,O
Cardiovasc,O
Qual,O
Outcomes,O
[,O
Internet,MISC
],O
2014,DATE
;,O
7:151156,NUMBER
.,O
Available,O
from,O
:,O
Westanmo,MISC
A,MISC
.,O
Marshall,PERSON
P,O
.,O
Jones,PERSON
E,O
.,O
Burns,PERSON
K,PERSON
.,O
Krebs,PERSON
EE,O
:,O
Opioid,O
Dose,O
Reduction,O
in,O
a,O
VA,ORGANIZATION
Health,ORGANIZATION
Care,ORGANIZATION
SystemImplementa,O
‐,O
tion,O
of,O
a,O
Primary,O
Care,O
Population,O
‐,O
Level,O
Initiative,O
.,O
Pain,O
Med,O
[,O
In,O
‐,O
ternet,O
],O
2015,DATE
;,O
16:10191026,NUMBER
.,O
Available,O
from,O
:,O
Godeau,PERSON
P,O
.,O
Guillevin,PERSON
L,PERSON
.,O
Fechner,PERSON
J,PERSON
.,O
Bletry,O
O,O
HG,O
:,O
Disorders,O
of,O
conduction,O
in,O
lupus,O
erythe,O
‐,O
matosus,O
:,O
Frequency,O
and,O
incidence,O
in,O
a,O
group,O
of,O
112,NUMBER
patients,O
.,O
Ann,PERSON
Med,ORGANIZATION
Interne,ORGANIZATION
McGhie,ORGANIZATION
TK,ORGANIZATION
.,O
Harvey,PERSON
P,O
.,O
Su,PERSON
J,PERSON
.,O
Anderson,PERSON
N,O
.,O
Tomlinson,PERSON
G,PERSON
.,O
Touma,PERSON
Z,O
:,O
Electrocardiogram,O
abnormalities,O
related,O
to,O
anti,O
‐,O
malari,O
‐,O
als,O
in,O
systemic,O
lupus,CAUSE_OF_DEATH
erythematosus,CAUSE_OF_DEATH
.,O
Clin,O
Exp,O
Costedoat,O
‐,O
Chalumeau,O
N,O
.,O
Hulot,PERSON
J,O
‐,O
S,O
.,O
Amoura,O
Z,O
.,O
Leroux,PERSON
G,PERSON
.,O
Lechat,PERSON
P,O
.,O
Funck,PERSON
‐,O
Brentano,O
C,O
.,O
Piette,PERSON
J,O
‐,O
C,O
:,O
Heart,O
conduction,O
disorders,O
related,O
to,O
antimalarials,O
toxicity,O
:,O
an,O
analysis,O
of,O
electrocardiograms,O
in,O
85,NUMBER
patients,O
treat,O
‐,O
ed,O
with,O
hydroxychloroquine,O
for,O
connective,O
tissue,O
Liu,PERSON
J,PERSON
.,O
Cao,PERSON
R,PERSON
.,O
Xu,PERSON
M,O
.,O
Wang,PERSON
X,PERSON
.,O
Zhang,PERSON
H,PERSON
.,O
Hu,O
H,O
.,O
Li,PERSON
Y,PERSON
.,O
Hu,O
Z,O
.,O
Zhong,PERSON
W,PERSON
.,O
Wang,PERSON
M,O
:,O
Lakkireddy,PERSON
DR,O
.,O
Chung,PERSON
MK,PERSON
.,O
Gopinathannair,PERSON
R,PERSON
.,O
et,O
al.,O
:,O
Guidance,O
for,O
Cardiac,O
Electrophysiology,O
During,O
the,O
COVID,O
‐,O
19,NUMBER
Pandemic,O
from,O
the,O
Heart,O
Rhythm,O
Society,O
COVID,O
‐,O
19,NUMBER
Task,O
Force,O
;,O
Electrophysiology,O
Section,O
of,O
the,O
American,ORGANIZATION
College,ORGANIZATION
of,ORGANIZATION
Cardiology,ORGANIZATION
;,O
and,O
the,O
Electrocardiography,O
and,O
Arrhythmias,ORGANIZATION
Committee,ORGANIZATION
of,O
the,O
Council,O
on,O
.,O
Circulation,O
[,O
Inter,O
‐,O
net,O
],O
2020,DATE
;,O
141,NUMBER
.,O
Available,O
from,O
:,O
Anand,PERSON
V,PERSON
.,O
Vakil,PERSON
K,PERSON
.,O
Tholakanahalli,PERSON
V,O
.,O
Li,PERSON
J,PERSON
‐,O
M,O
.,O
McFalls,PERSON
E,O
.,O
Adabag,O
S,O
:,O
Discontinuation,O
of,O
Dofetilide,O
From,O
QT,O
Prolongation,O
and,O
Ventricular,O
Tachycardia,O
in,O
the,O
Real,O
World,O
.,O
JACC,ORGANIZATION
Clin,ORGANIZATION
Electrophysiol,ORGANIZATION
[,O
Internet,MISC
],O
2016,DATE
;,O
2:777781,NUMBER
.,O
Avail,O
‐,O
able,O
from,O
:,O
Ko,PERSON
B,PERSON
.,O
Garcia,PERSON
S,O
.,O
Mithani,PERSON
S,O
.,O
Tholakanahalli,PERSON
V,PERSON
.,O
Adabag,O
S,O
:,O
Risk,O
of,O
acute,O
kidney,O
injury,O
in,O
patients,O
who,O
undergo,O
coronary,O
an,O
‐,O
giography,O
and,O
cardiac,O
surgery,CAUSE_OF_DEATH
in,O
close,O
succession,O
.,O
Eur,PERSON
Heart,PERSON
J,PERSON
[,O
Internet,MISC
],O
2012,DATE
;,O
33:20652070,NUMBER
.,O
Available,O
from,O
:,O
Richardson,PERSON
S,O
.,O
Hirsch,ORGANIZATION
JS,ORGANIZATION
.,O
Narasimhan,PERSON
M,O
.,O
et,O
al.,O
:,O
Presenting,O
Characteristics,O
.,O
Co,O
‐,O
morbidities,O
.,O
and,O
Outcomes,O
Among,O
5700,NUMBER
Patients,O
Hospitalized,O
With,O
COVID,O
‐,O
19,NUMBER
in,O
the,O
New,CITY
York,CITY
City,CITY
Area,LOCATION
.,O
JAMA,O
[,O
Internet,MISC
],O
2020,DATE
;,O
323:2052,NUMBER
.,O
Available,O
from,O
:,O
COVID,O
‐,O
19,NUMBER
Treatment,O
Guidelines,O
[,O
Inter,O
‐,O
net,O
],O
.,O
Natl.,O
Inst,O
.,O
Heal,O
.,O
2020,DATE
[,O
cited,O
2020,DATE
Apr,DATE
25,DATE
],O
.,O
.,O
Li,PERSON
Z,PERSON
.,O
Wu,PERSON
M,PERSON
.,O
Yao,PERSON
J,PERSON
.,O
et,O
al.,O
:,O
Caution,O
on,O
Kidney,O
Dysfunctions,O
of,O
COVID,O
‐,O
19,NUMBER
Pa,STATE_OR_PROVINCE
‐,O
tients,O
.,O
SSRN,O
Jain,RELIGION
S,O
.,O
Workman,PERSON
V,O
.,O
Ganeshan,PERSON
R,PERSON
.,O
Obasare,O
ER,O
.,O
Burr,PERSON
A,O
.,O
DeBiasi,O
RM,O
.,O
Freeman,PERSON
J,PERSON
V.,PERSON
.,O
Akar,PERSON
J,PERSON
.,O
Lampert,PERSON
R,O
.,O
Rosenfeld,PERSON
LE,O
:,O
En,O
‐,O
hanced,O
ECG,O
monitoring,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Hear,O
Rhythm,O
[,O
Inter,O
‐,O
net,O
],O
2020,DATE
;,O
S1547,O
‐,O
5271:3042130425,NUMBER
.,O
Available,O
from,O
:,O
Torp,O
‐,O
Pedersen,PERSON
C,O
.,O
Mller,PERSON
M,O
.,O
Bloch,PERSON
‐,O
Thomsen,ORGANIZATION
PE,ORGANIZATION
.,O
Kber,O
L,O
.,O
Sande,PERSON
E,PERSON
.,O
Egstrup,PERSON
K,PERSON
.,O
Agner,PERSON
E,O
.,O
Carlsen,PERSON
J,PERSON
.,O
Videbk,PERSON
J,PERSON
.,O
Marchant,PERSON
B,O
.,O
Camm,O
AJ,O
:,O
Dofetilide,MISC
in,O
Pa,STATE_OR_PROVINCE
‐,O
tients,O
with,O
Congestive,CAUSE_OF_DEATH
Heart,CAUSE_OF_DEATH
Failure,CAUSE_OF_DEATH
and,O
Left,O
Ventricular,O
Dys,O
‐,O
function,O
.,O
N,O
Engl,O
J,O
Med,O
[,O
Internet,MISC
],O
1999,DATE
;,O
341:857,NUMBER
Weeke,O
P,O
.,O
Delaney,PERSON
J,O
.,O
Mosley,PERSON
JD,O
.,O
Wells,O
Q,O
.,O
Van,O
Driest,O
S,O
.,O
Norris,PERSON
K,PERSON
.,O
Kucera,PERSON
G,PERSON
.,O
Stubble,O
‐,O
field,O
T,O
.,O
Roden,PERSON
DM,O
:,O
QT,O
variability,O
during,O
initial,O
exposure,O
to,O
so,O
‐,O
talol,O
:,O
experience,O
based,O
on,O
a,O
large,O
electronic,O
medical,O
record,O
.,O
EP,O
Eur,MISC
[,MISC
Internet,MISC
],O
2013,DATE
;,O
15:17911797,NUMBER
.,O
Available,O
from,O
:,O
Jordan,CITY
P,O
.,O
Brookes,ORGANIZATION
JG,ORGANIZATION
.,O
Nikolic,PERSON
G,PERSON
.,O
Le,ORGANIZATION
Couteur,ORGANIZATION
DG,ORGANIZATION
.,O
Le,PERSON
Couteur,PERSON
D,O
:,O
Hydroxy,O
‐,O
chloroquine,O
Overdose,CAUSE_OF_DEATH
:,O
Toxicokinetics,O
and,O
Management,O
.,O
J,PERSON
Toxicol,PERSON
Clin,PERSON
Toxicol,PERSON
Taylor,PERSON
&,O
Francis,PERSON
.,O
therapy,O
was,O
associated,O
with,O
greater,O
mortality,O
in,O
univariable,O
analysis,O
but,O
not,O
after,O
adjust,O
‐,O
ment,O
for,O
age,O
.,O
sex,O
and,O
comorbidities,O
.,O
All,O
patients,O
(,O
n,O
=,O
819,NUMBER
),O
Age,O
.,O
years,DURATION
Male,O
.,O
n,O
(,O
%,O
),O
Hypertension,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Coronary,O
artery,O
disease,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Diabetes,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Atrial,O
fibrillation,O
.,O
n,O
(,O
%,O
),O
Chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
End,O
‐,O
stage,O
renal,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
SLE,O
.,O
n,O
(,O
%,O
),O
Magnesium,O
.,O
mg,O
/,O
dl,O
Potassium,O
.,O
mmol,O
/,O
L,O
Creatinine,O
.,O
mg,O
/,O
dl,O
eGFR,O
.,O
ml,O
/,O
min,DURATION
/,O
1.73,NUMBER
m2,O
eGFR,O
.,O
ml,O
/,O
min,DURATION
Continuous,O
variables,O
were,O
rep,O
‐,O
resented,O
as,O
mean,O
(,O
standard,O
deviation,O
),O
Abbreviations,O
:,O
eGFR,O
=,O
esti,O
‐,O
mated,O
glomerular,O
filtration,O
rate,O
;,O
HCQ,O
=,O
hydroxychloroquine,O
;,O
SLE,O
=,O
systemic,O
lupus,CAUSE_OF_DEATH
erythematosus,CAUSE_OF_DEATH
All,O
patients,O
P,O
value,O
*,O
Ventricular,O
rate,O
.,O
bpm,O
QRS,O
duration,O
.,O
msec,O
QT,O
interval,O
.,O
msec,O
QTc,O
‐,O
Bazett,O
.,O
msec,O
QTc,O
‐,O
Friderica,O
.,O
msec,O
Continuous,O
variables,O
were,O
represented,O
as,O
mean,O
(,O
standard,O
deviation,O
),O
*,O
Comparison,O
of,O
QTc,O
470,NUMBER
msec,O
vs.,O
QTc,O
>,O
470,NUMBER
msec,O
Age,O
.,O
years,DURATION
Male,O
.,O
n,O
(,O
%,O
),O
Hypertension,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Coronary,O
artery,O
disease,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Diabetes,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Atrial,O
fibrillation,O
.,O
n,O
(,O
%,O
),O
Chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
Magnesium,O
.,O
mg,O
/,O
dl,O
Potassium,O
.,O
mmol,O
/,O
L,O
Creati,O
‐,O
nine,NUMBER
.,O
mg,O
/,O
dl,O
eGFR,O
.,O
ml,O
/,O
min,DURATION
/,O
1.73,NUMBER
m2,O
Heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
.,O
n,O
(,O
%,O
),O
eGFR,O
.,O
ml,O
/,O
min,DURATION
P,O
value,O
*,O
Continuous,O
variables,O
were,O
represented,O
as,O
mean,O
(,O
standard,O
deviation,O
),O
Abbreviations,O
:,O
eGFR,O
=,O
estimated,O
glomerular,O
filtration,O
rate,O
;,O
HCQ,O
=,O
hydroxychloroquine,O
;,O
SLE,O
=,O
systemic,O
lupus,O
erythematosus,O
*,O
Comparison,O
of,O
QTc,O
470,NUMBER
msec,O
vs.,O
QTc,O
>,O
470,NUMBER
msec,O
On,O
treatment,O
P,O
value,O
Ventricular,O
rate,O
.,O
bpm,O
QRS,O
duration,O
.,O
msec,O
QT,O
in,O
‐,O
terval,O
.,O
msec,O
QTc,O
‐,O
Bazett,O
.,O
msec,O
QTc,O
‐,O
Framingham,CITY
.,O
msec,O
QTc,O
‐,O
Friderica,O
.,O
msec,O
Continuous,O
variables,O
were,O
represented,O
as,O
mean,O
(,O
standard,O
de,O
‐,O
viation,O
),O
